ArticleIn vivo (Athens, Greece)
Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimCase reports describe prolonged COVID19 shedding in patients with malignant hematological disease. Similarly, we observed extended viral shedding in hemato-oncological patients (HP) at our SARS-CoV-2 unit. This raises the question of whether HP are more susceptible to prolonged SARS-CoV-2 shedding and which aspects of immunosuppression contribute to this phenomenon. PATIENTS AND
methodsData from HP treated at a single center between 02/2022 and 02/2023 were retrospectively analyzed. Overall, 47 HP with a positive SARS-CoV-2 PCR test were included. Additional data on 16 HP were retrieved from literature. The duration of SARS-CoV-2 positivity (t[SARS+]) was compared between subgroups with different diagnoses, immune status, and HP with and without medical treatment of SARS-CoV-2.
resultst[SARS+] of HP was 47 days [interquartile range (IR)=25-95] and 12 HP (19%) were still positive by the end of the follow-up. In our cohort, four HP died while still shedding SARS-CoV-2 [t[SARS+]=47 days (IR=33.5-86)]. Different oncological diagnoses did not influence t[SARS+]. HP under steroids had a significantly longer average t[SARS+] (108 days
conclusionProlonged viral shedding is a common occurrence in HP. Our data illustrate that HP under immune suppression show a significantly longer t[SARS+]. Furthermore, we demonstrate that vaccination influences the length of viral shedding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.